CG Invites Co., Ltd. (KOSDAQ:083790)

Market Cap	128.41B
Revenue (ttm)	9.62B
Net Income (ttm)	-48.80B
Shares Out	76.89M
EPS (ttm)	-635.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,961
Average Volume	164,344
Open	1,715.00
Previous Close	1,715.00
Day's Range	1,666.00 - 1,722.00
52-Week Range	1,590.00 - 2,795.00
Beta	0.46
RSI	38.38
Earnings Date	Aug 13, 2025

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 83
• Stock Exchange: KOSDAQ
• Ticker Symbol: 083790

Financial Performance

In 2024, CG Invites's revenue was 7.25 billion, an increase of 48.67% compared to the previous year's 4.88 billion. Losses were -51.54 billion, 5.36% more than in 2023.